This site is not optimized for mobile devices. For the best mobile experience we suggest you download our mobile app!
Download on App Store App Store Icon App Store Google Play Store Icon Google Play

Anxiolytics & ARVs

Drug-drug Interactions between Anxiolytics and ARVs

Drug-drug Interactions between Anxiolytics and ARVs.png

Colour Legend from EACS v10.1 2020

Legend
↑     Potential elevated exposure of the anxiolytic therapy
↓     Potential decreased exposure of the anxiolytic therapy
↔   No significant effect
D     Potential decreased exposure of ARV drug
E     Potential elevated exposure of ARV drug

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies

ATV/c:
ATV co-formulated with COBI (300/150 mg qd)

DRV/c:
DRV co-formulated with COBI (800/150 mg qd)

CAB/RPV:
CAB and RPV im long acting injections

BZD (benzodiazepines)
SSRI (selective serotonin reuptake inhibitors)
SNRI (serotonin and norepinephrine reuptake inhibitors)

Interactions with ABC, FTC, 3TC, ZDV
ABC, FTC, 3TC, ZDV:
No clinically relevant interactions expected

Interactions with cabotegravir (oral)
None

Interactions with ibalizumab
None

Comments

  1. ECG monitoring is recommended.
  2. Caution as both drugs can induce QT interval prolongation.

EFV prolonged the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6*6/*6 allele (516T variant). Coadministration with a drug with a known risk of TdP is contraindicated in the EFV European label.

^ LEN causes moderate inhibition of CYP3A4 and, when discontinued, remains in the circulation for prolonged periods. Residual concentrations of LEN may affect the exposure of sensitive CYP3A4 substrates and/ or narrow therapeutic index drugs that are initiated within 9 months after the last subcutaneous dose of LEN.

Further Information
For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to: http://www.hiv-druginteractions.org (University of Liverpool)